组蛋白去乙酰化酶在缺血性脑卒中后血脑屏障损伤中作用的研究进展

Research Progress on the Role of Histone Deacetylase in Blood-brain Barrier Injury After Ischemic Stroke

血脑屏障(blood-brain barrier,BBB)损伤是缺血性脑卒中的病理特征之一,会促进神经炎症和出血性转化。本文对各类组蛋白去乙酰化酶(histone deacetylase,HDAC)在缺血性脑卒中后BBB损伤中的作用进行综述,发现使用HDAC抑制剂靶向抑制HDAC3、HDAC9、Sirt5或使用Sirt激活剂上调Sirt3和Sirt6能减轻患者的术后炎症、降低出血性转化风险,从而挽救患者在缺血性脑卒中后的BBB损伤、扩展r-tPA用药时间窗、促进患者的神经功能恢复。

Disruption of the blood brain barrier(BBB)is one of the pathophysiological features of ischemic stroke,which will lead to neuroinflammation and hemorrhagic transformation.This paper summarize the research progress on the role of all kinds of histone deacetylase(HDAC)on BBB injury after ischemic stroke,and find that HDAC inhibitors that be used to target HDAC3,HDAC9 and Sirt5 or Sirt activators or be used to target Sirt3 and Sirt6,can reduce postoperative inflammation,reduce the risk of hemorrhagic transformation.Thus,it can save patients from BBB injury after ischemic stroke,extend the time window of r-tPA medication,and promote the recovery of patients’neurological function.